More about

Juvenile Arthritis

News
November 08, 2021
3 min read
Save

FROST: Biologics most common initial therapy for systemic JIA

FROST: Biologics most common initial therapy for systemic JIA

Initial biologic therapy is now the most common treatment for children with systemic juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry, according to data presented at ACR Convergence 2021.

News
November 08, 2021
3 min read
Save

'Starting biologics early' with DMARDs may boost polyarticular JIA outcomes at 2 years

'Starting biologics early' with DMARDs may boost polyarticular JIA outcomes at 2 years

Early, aggressive treatment with a biologic alongside a conventional DMARDs for juvenile idiopathic arthritis achieved clinically inactive disease at 24 months more frequently than other strategies, said a presenter at ACR Convergence 2021.

News
November 08, 2021
3 min read
Save

Racial disparities persist in renal outcomes among children with lupus

Racial disparities persist in renal outcomes among children with lupus

Black children with lupus are significantly more likely than white children to have an adverse renal outcome at any hospital encounter, despite an overall decrease in said outcomes since 2006, according to data presented at ACR Convergence 2021.

News
November 04, 2021
2 min read
Save

Regular eye exam reminders bolster uveitis awareness in families with juvenile arthritis

Regular eye exam reminders bolster uveitis awareness in families with juvenile arthritis

Eye exam reminders at every visit are associated with higher uveitis knowledge among patients with juvenile idiopathic arthritis and their parents, according to data published in Pediatric Rheumatology.

News
September 09, 2021
2 min read
Save

COVID-19 lockdown linked to higher flare rate in patients with JIA

COVID-19 lockdown linked to higher flare rate in patients with JIA

Living under COVID-19 lockdown was associated with a higher rate of joint inflammation in children with juvenile idiopathic arthritis, according to data from an Italian cohort published in Arthritis Care & Research.

News
July 02, 2021
2 min read
Save

STOP-JIA: 'Early combination' DMARD, biologic may improve key outcomes in polyarticular JIA

STOP-JIA: 'Early combination' DMARD, biologic may improve key outcomes in polyarticular JIA

Three strategies aimed at starting patients with polyarticular juvenile idiopathic arthritis on different combinations of DMARDs and biologics resulted in similar rates of clinically inactive disease without glucocorticoids at 12 months, according to data.

News
April 26, 2021
2 min read
Save

Parents report 'high frequency' of JIA medication side effects in 67% of children

Parents report 'high frequency' of JIA medication side effects in 67% of children

Parents reported that two-thirds of children with juvenile idiopathic arthritis demonstrate drug side effects that impact their quality of life within 1 year of diagnosis, according to data published in Arthritis Care & Research.

News
March 10, 2021
3 min read
Save

Inflammatory joint diseases confer 'low excess risk' for COVID-19 hospitalization, death

Inflammatory joint diseases confer 'low excess risk' for COVID-19 hospitalization, death

During the early months of the COVID-19 pandemic, increased all-cause mortality in patients with rheumatoid arthritis and other inflammatory joint diseases largely mirrored that of the general population, according to data.

News
February 18, 2021
2 min read
Save

Risk/benefit profiles similar for subcutaneous, IV tocilizumab in systemic JIA

Risk/benefit profiles similar for subcutaneous, IV tocilizumab in systemic JIA

Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in patients with systemic juvenile idiopathic arthritis, according to findings published in Rheumatology.

News
February 05, 2021
2 min read
Save

Systemic JIA subset linked to IL-18 may be at increased risk for cytokine storm

Systemic JIA subset linked to IL-18 may be at increased risk for cytokine storm

A subset of patients with systemic juvenile idiopathic arthritis with elevated interleukin-18 markers could face “increased risk” for macrophage activation syndrome, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

View more